Health Bulletin 30

NHRC member Priyank Kanoongo, terming the move a ''time bomb'', which, if ''not defused'', will ''explode inside families''. For more details, check out the full story on the link below: Doctors, Rights Experts raise alarm over proposal to lower age of consent Delhi HC Issues Notice to NBE, Centre Over DNB Revaluation Clause Challenge The Delhi High Court has sought a response from the National Board of Examination (NBE) and the Centre on a plea filed by a DNB trainee doctor from Gangaram Hospital challenging the evaluation rules in the Diplomate National Board exam. The petitioner argued that the current clause allows revaluation only if an answer is wrongly marked “not attempted,” leaving no scope to challenge 'arbitrary' evaluation. She claimed her answer sheets showed discrepancies, and denial of revaluation had unjustly barred her from the practical exam, jeopardizing her career. For more details, check out the full story on the link below: Doctor challenges 'arbitrary' revaluation clause in DNB exam- Delhi HC issues notice to NBE, Centre 100 Additional Delhi Hospitals to Be Added Under Ayushman Bharat Soon Delhi Health Minister Dr Pankaj Singh on Thursday announced that the government will add 100 more hospitals under the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) in the next 10 days. This move will increase the total number of empanelled hospitals in the capital to 165. The updated list is expected to include prominent private hospitals such as Fortis Healthcare. A formal launch of the expanded network is scheduled for the first week of September. According to the National Health Authority (NHA), which oversees the implementation of AB-PMJAY across India, 151 hospitals in Delhi are currently empanelled under the scheme—107 private and 44 government-run. For more details, check out the full story on the link below: Delhi Govt to empanel 100 additional hospitals under Ayushman Bharat CDSCO Flags 46 Drug Batches for Failing Quality Tests in July The Central Drugs Standard Control Organization (CDSCO) has declared 46 batches of medicines as "Not of Standard Quality" (NSQ) after drug samples tested by its regional and central laboratories in July 2025 failed to meet required pharmacopeial standards. The flagged medicines include widely prescribed formulations such as antibiotics, cardiac drugs, gastrointestinal medicines, hormonal injections, and pain relief products. These include Azithromycin Tablets IP (Aziventis-500) manufactured by Gnosis Pharmaceuticals, Heparin Injection IP 1000 IU/ml (Flagorin) manufactured by Divine Laboratories, Amikacin Sulphate Injection manufactured by SAI Parenterals, Amoxycillin and Potassium Clavulanate Tablets I.P. 625 mg manufactured by Hindustan Antibiotics, Dexamethasone Tablets IP 4mg (Dexatore-4) manufactured by United Bioceuticals, and others. For more details, check out the full story on the link below: